Stocktoria
IDEXX LABORATORIES INC /DE IDXX
Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1991-06-21
IDEXX LABORATORIES INC /DE financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B | $3.9B | $3.7B | $3.4B | $3.2B | $2.7B | $2.4B | $2.2B | $2.0B | $1.8B |
| Gross profit | $2.7B | $2.4B | $2.2B | $2.0B | $1.9B | $1.6B | $1.4B | $1.2B | $1.1B | $975.4M |
| R&D expense | $251.2M | $219.8M | $191.0M | $254.8M | $161.0M | $141.2M | $133.2M | $117.9M | $109.2M | $101.1M |
| Operating income | $1.4B | $1.1B | $1.1B | $898.8M | $932.0M | $694.5M | $552.8M | $491.3M | $413.0M | $350.2M |
| Interest expense | — | — | $41.6M | $39.9M | $29.8M | $33.1M | $31.1M | $34.7M | $37.2M | $32.0M |
| Income tax | $264.7M | $222.0M | $216.1M | $180.9M | $157.8M | $79.9M | $94.4M | $80.7M | $117.8M | $99.8M |
| Net income | $1.1B | $887.9M | $845.0M | $679.1M | $744.8M | $581.8M | $427.7M | $377.0M | $263.1M | $222.0M |
| EPS (diluted) | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 |
| Operating cash flow | $1.2B | $929.0M | $906.5M | $543.0M | $755.5M | $648.1M | $459.2M | $400.1M | $373.3M | $338.9M |
| Free cash flow | $1.1B | $808.1M | $772.9M | $394.1M | $636.0M | $541.1M | $304.2M | $284.3M | $298.9M | $274.2M |
| Cash & equivalents | $180.1M | $288.3M | $453.9M | $112.5M | $144.5M | $383.9M | $90.3M | $123.8M | $187.7M | $154.9M |
| Inventory | $377.8M | $381.9M | $380.3M | $367.8M | $269.0M | $209.9M | $195.0M | $173.3M | $164.3M | $158.0M |
| Total assets | $3.4B | $3.3B | $3.3B | $2.7B | $2.4B | $2.3B | $1.8B | $1.5B | $1.7B | $1.5B |
| Total liabilities | $1.7B | $1.7B | $1.8B | $2.1B | $1.7B | $1.7B | $1.7B | $1.5B | $1.8B | $1.6B |
| Shareholders' equity | $1.6B | $1.6B | $1.5B | $608.7M | $690.0M | $632.8M | $177.8M | -$9.5M | -$54.1M | -$108.4M |
Growth · year-over-year · Revenue CAGR 10.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +10.4% | +6.5% | +8.7% | +4.7% | +18.8% | +12.5% | +8.8% | +12.4% | +10.9% | +10.8% |
| Net income growth | +19.3% | +5.1% | +24.4% | -8.8% | +28.0% | +36.0% | +13.4% | +43.3% | +18.5% | +15.6% |
| EPS growth | +22.6% | +6.1% | +25.3% | -6.6% | +28.2% | +37.2% | +14.8% | +44.9% | +20.5% | +19.0% |
| Free cash flow growth | +30.8% | +4.6% | +96.1% | -38.0% | +17.5% | +77.9% | +7.0% | -4.9% | +9.0% | +97.4% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.